US 10322113
Pharmaceutical compositions directly targeting FKBP52 for the treatment of prostate cancer and methods of using same
granted A61KA61K31/4184A61K45/06
Quick answer
US patent 10322113 (Pharmaceutical compositions directly targeting FKBP52 for the treatment of prostate cancer and methods of using same) held by The Board of Regents of the University of Texas System expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 4
- CPC classes
- A61K, A61K31/4184, A61K45/06